Previsión

Comprar	0
Mantener	0
Vender	1

Noticias Ir al feed de noticias

Euroapi to mothball metamizole production in Frankfurt and cut workforce

Euroapi will mothball its production facility for the painkiller metamizole in Frankfurt-Höchst at the end of the year and reduce the number of employees on site from around 750 to under 700. The company is withdrawing from several active ingredients for price-competitiveness reasons and plans to stepwise exit 13 substances by 2027. Across Europe many active-ingredient productions have been shifted in favor of Asian suppliers, which is why France is providing state funds to modernize Euroapi sites. Policymakers and industry are now debating subsidy programs and procurement rules to strengthen supply security and local value creation in active-ingredient production. » Más en faz.net

Datos financieros de la empresa

En el último trimestre, EUROAPI tuvo unos ingresos de 355,97M€ y un beneficio neto de −141,29M€

(EUR)	jun 2026	YoY
Ingresos	+355,97M	-
Beneficio bruto	+55,72M	-
Beneficio neto	−141,29M	-
EBITDA	+83,77M	-

Datos fundamentales

Métrica	Valor
Capitalización bursátil	+140,30M€
Número de acciones	95,57M
Máximo/mínimo de 52 semanas	+3,08€ - +1,00€
Dividendos	No
Beta	0,98
Ratio P/E	−0,28
Ratio PEG	0,00
Ratio P/B	+0,19
Ratio P/S	+0,11

Perfil de la empresa

Euroapi SA entwickelt, produziert, vermarktet und vertreibt pharmazeutische Wirkstoffe und Zwischenprodukte für die Formulierung von Human- und Tierarzneimitteln. Das Unternehmen wurde im Jahr 2021 gegründet und hat seinen Sitz in Paris, Frankreich.